Skip to content
DataLookout
Menu

NCT07158437

Phase 1 Study of SL-325 in Healthy Volunteers

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 15 words
    • Trial completed
    • Primary and study completion dates changed from estimate of Jul 2026 to Jul 16, 2026
    • Secondary endpoints: details revised at 4 of 13 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Sep 2025 to Sep 18, 2025
    • Site details revised
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Safety and Tolerability
Timeframe: Day 1 through 75 days after last dose

Secondary (13)

Pharmacokinetics (PK): Cmax
Pharmacokinetics (PK): Tmax
Pharmacokinetics (PK): Ctrough
Pharmacokinetics (PK): AUC
Pharmacokinetics (PK): T1/2
Show 8 moreShow less
Pharmacokinetics (PK): CL
Pharmacokinetics (PK): Vz
Immunogenicity: Number/proportion of participants with positive or negative anti-drug antibody (ADA) titers
Immunogenicity: Number/proportion of participants with neutralizing anti-drug antibodies
Immunogenicity: Time to onset and duration of anti-drug antibodies
Immunogenicity: Number/proportion of participants with transient vs persistent anti-drug antibodies
Receptor Occupancy: Percent of DR3-positive T cells bound by SL-325
Receptor Occupancy: Duration of DR3-positive T cell binding by SL-325

Arms and interventions

SAD: SL-325Experimental

Participants will receive a single dose of SL-325 in escalating dose cohorts

SAD: PlaceboPlacebo comparator

Participants will receive a single dose of placebo (normal saline)

MAD: SL-325Experimental

Participants will receive a three doses of SL-325 in escalating dose cohorts

MAD: PlaceboPlacebo comparator

Participants will receive a three doses of placebo (normal saline)

Biologicals: SL-325

Other: Placebo (Normal Saline)

Sites

1 site in 1 country

  • CelerionLincoln, Nebraska, United States